Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to -$57.7 million.

  • Beam Therapeutics' Change in Accured Expenses rose 120.07% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.7 million, marking a year-over-year decrease of 163.65%. This contributed to the annual value of -$57.7 million for FY2024, which is 185.25% down from last year.
  • Beam Therapeutics' Change in Accured Expenses amounted to -$57.7 million in FY2024, which was down 185.25% from $67.7 million recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' Change in Accured Expenses peaked at $67.7 million during FY2023, and registered a low of -$57.7 million during FY2024.
  • Its 3-year average for Change in Accured Expenses is -$2.3 million, with a median of -$16.9 million in 2022.
  • In the last 5 years, Beam Therapeutics' Change in Accured Expenses skyrocketed by 524.22% in 2021 and then plummeted by 185.25% in 2024.
  • Beam Therapeutics' Change in Accured Expenses (Yearly) stood at $7.0 million in 2020, then skyrocketed by 524.22% to $43.9 million in 2021, then tumbled by 138.56% to -$16.9 million in 2022, then spiked by 499.59% to $67.7 million in 2023, then plummeted by 185.25% to -$57.7 million in 2024.